IL13RA2 and glioblastoma: We have previously shown the ability to reprogram IL13Rα2 CAR T cells to secrete checkpoint blockade minibodies and that these can augment CAR T treatment in subcutaneously implanted murine GBM xenograft models, with results similar to CAR T and checkpoint Ab combination therapy (77).